PSMA PET Combined With MRI for the Detection of PCa
A phase 3 trial of Gallium-68 gozetotide in prostate cancer, run by Telix Pharmaceuticals (Innovations) Pty Limited, now recruiting.
Overview
PSMA PET Combined With MRI for the Detection of PCa is a phase 3 interventional study registered as NCT07052214 by Telix Pharmaceuticals (Innovations) Pty Limited, with 338 participants planned, started 2025-08-18 and due to reach its primary completion in 2027-01. Interventions recorded: 68Ga-PSMA-11. Conditions listed: PCA, Prostate Cancer, Prostatic Neoplasm, PSMA PET. No results are recorded here; the registry entry is the source.
Setting
A Single Arm, Multicenter, Prospective, Open Label, Longitudinal Phase 3 Study of Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) Combined With Magnetic Resonance Imaging (MRI) Compared to Standard of Care (SOC) for the Detection of Prostate Cancer (PCa).
Phase
Phase 3
Sponsor
Telix Pharmaceuticals (Innovations) Pty Limited
Registry
Enrolled
338
Similar pages
not linked directly; found by shared links- TreatmentIlluccix (kit for Ga-68 gozetotide)
Shares Gallium-68 gozetotide (PSMA-11), Telix Pharmaceuticals, Prostate cancer.
- TrialThe Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
Shares Telix Pharmaceuticals, Prostate cancer.
- TreatmentLocametz (kit for Ga-68 gozetotide)
- InstitutionUCLA Jonsson Comprehensive Cancer Center